期刊
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 55, 期 20, 页码 2187-2195出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2010.01.039
关键词
acute coronary syndromes; percutaneous coronary intervention; review; transradial
资金
- Terumo Medical
- Portola Pharmaceuticals
- Momenta Pharmaceuticals
- Cordis Corporation
- Medtronic
- Abbott Vascular
- Cordis
- GE Healthcare
- AstraZeneca
- Eisi Medical Research
- Hoffman-LaRoche
- Boston Scientific
- Angel Medical
- Bristol- Myers Squibb
- Osiris Therapeutics Inc
Periprocedural bleeding complications after percutaneous coronary intervention (PCI) are associated with increased short- and long-term morbidity and mortality. Although clinical trials have primarily assessed pharmacological strategies for reducing bleeding risk, there is a mounting body of evidence suggesting that adoption of a transradial rather than a transfemoral approach to PCI may permit greater reductions in bleeding risk than have been achieved with pharmacological strategies alone. However, despite a long history of use, a lack of widespread uptake by physicians coupled with the technological limitations of available devices has in the past confined transradial PCI to the status of a niche procedure, and many operators lack experience in this technique. In this review, we examine the history of the transradial approach to PCI and discuss some of the circumstances that have hitherto limited its appeal. We then review the current state of the peer-reviewed literature supporting its use and summarize the unresolved issues affecting broader application of this technique, including lack of operator familiarity and an insufficient evidence base for guiding practice. Finally, we describe potential directions for future investigation in the transradial realm. (J Am Coll Cardiol 2010;55:2187-95) (C) 2010 by the American College of Cardiology Foundation
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据